Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ERBB3 P262H |
| Gene Variant Detail | |
| Relevant Treatment Approaches | HER inhibitor (Pan) HER2 Inhibitor HER3 Inhibitor Pertuzumab Trastuzumab |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| ERBB3 P262H | Advanced Solid Tumor | sensitive | HER2 Inhibitor | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) P262H (PMID: 23680147). | 23680147 |
| ERBB3 P262H | Advanced Solid Tumor | sensitive | Duligotuzumab | Preclinical | Actionable | In a preclinical study, MEHD7945A inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) P262H (PMID: 23680147). | 23680147 | |
| ERBB3 P262H | Advanced Solid Tumor | sensitive | Trastuzumab | Trastuzumab | Preclinical | Actionable | In a preclinical study, Herceptin (trastuzumab) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) P262H (PMID: 23680147). | 23680147 |
| ERBB3 P262H | Advanced Solid Tumor | sensitive | Pertuzumab | Pertuzumab | Preclinical | Actionable | In a preclinical study, Perjeta (pertuzumab) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) P262H (PMID: 23680147). | 23680147 |
| ERBB3 P262H | Advanced Solid Tumor | resistant | Cetuximab | Preclinical | Actionable | In a preclinical study, transformed cell lines expressing ERBB3 (HER3) P262H demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 23680147). | 23680147 | |
| ERBB3 P262H | Advanced Solid Tumor | sensitive | Pictilisib | Preclinical | Actionable | In a preclinical study, the PI3K inhibitor GDC-0941 inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) P262H (PMID: 23680147). | 23680147 | |
| ERBB3 P262H | Advanced Solid Tumor | sensitive | Mirdametinib + Pictilisib | Preclinical | Actionable | In a preclinical study, the combination of GDC-0941 and Gomekli (mirdametinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) P262H (PMID: 23680147). | 23680147 | |
| ERBB3 P262H | breast cancer | sensitive | Patritumab deruxtecan | Preclinical - Cell culture | Actionable | In a preclinical study, Patritumab deruxtecan (U3-1402) treatment inhibited growth of a breast cancer cell line expressing ERBB3 (HER3) P262H in culture (PMID: 35503762). | 35503762 |